ARS Pharmaceuticals Inc.
Last updated September 27, 2026
Organization details
- Legal name
- ARS Pharmaceuticals Inc.
- Former names
- Silverback Therapeutics, Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- SAN Diego
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- SPRY
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001671858
- EIN
- 81-1489190
Board of directors
-
Brent L. Saunders · DirectorSince 2023
-
Laura Shawver · DirectorSince 2023
-
Michael Kelly · DirectorSince 2023
-
Peter A. Thompson · DirectorSince 2023
- Since 2023
-
Phillip M. Schneider · DirectorSince 2023
-
Pratik Shah · DirectorSince 2023
-
Rajeev Dadoo · DirectorSince 2023
- Since 2023
-
Richard E. Lowenthal · Director · PRESIDENT AND CEOSince 2023
-
Saqib Islam · DirectorSince 2023
Chief executives
Richard E. Lowenthal
· PRESIDENT AND CEO
Dates unknown
Director election results
Annual meeting of June 24, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
58.3%
-
68.4%
-
78.1%
Board connections
7 of this board's directors also sit on 31 other boards.
- via Peter A. Thompson, Peter Kolchinsky and Rajeev M. Shah
- via Peter Kolchinsky and Rajeev M. Shah
- via Peter Kolchinsky and Rajeev M. Shah
- via Peter Kolchinsky and Rajeev M. Shah
- via Peter Kolchinsky and Rajeev M. Shah
- via Peter Kolchinsky and Rajeev M. Shah
- via Peter Kolchinsky and Rajeev M. Shah
- via Peter Kolchinsky and Rajeev M. Shah
- via Peter Kolchinsky and Rajeev M. Shah
- via Peter Kolchinsky and Rajeev M. Shah
- via Peter Kolchinsky and Rajeev M. Shah
- via Peter Kolchinsky and Rajeev M. Shah
- via Peter Kolchinsky and Rajeev M. Shah
- via Peter Kolchinsky and Rajeev M. Shah
- via Peter Kolchinsky and Rajeev M. Shah
- via Peter Kolchinsky and Rajeev M. Shah
- via Peter Kolchinsky and Rajeev M. Shah
- via Peter Kolchinsky and Rajeev M. Shah
- via Peter Kolchinsky and Rajeev M. Shah
- via Peter Kolchinsky and Rajeev M. Shah
- via Peter Kolchinsky and Rajeev M. Shah
- via Peter Kolchinsky and Rajeev M. Shah
- via Peter Kolchinsky and Rajeev M. Shah
- via Peter Kolchinsky and Rajeev M. Shah
- via Brent L. Saunders
- via Peter A. Thompson
- via Pratik Shah
- via Peter A. Thompson
- via Saqib Islam
- via Laura Shawver
- via Brent L. Saunders
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $1,949,299
- 5 sales by 4 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 12, 2026 | Karas Eric Officer (Chief Commercial Officer) | Option exercise | +25,000 | $1.50 | $37,500 |
| Jun 12, 2026 | Fitzpatrick Alexander A Officer (Chief Legal Officer) | Open-market sale | −3,355 | $10.00 | $33,550 |
| Jun 12, 2026 | Karas Eric Officer (Chief Commercial Officer) | Open-market sale | −25,000 | $10.00 | $250,000 |
| Nov 13, 2025 | Dorsey Brian Officer (Chief Operating Officer) | Option exercise | +21,828 | $0.64 | $13,970 |
| Nov 13, 2025 | Dorsey Brian Officer (Chief Operating Officer) | Open-market sale | −21,828 | $8.71 | $190,122 |
| Nov 12, 2025 | Chakma Justin Officer (Chief Business Officer) | Option exercise | +30,000 | $0.84 | $25,200 |
| Nov 12, 2025 | Pratik Shah Director | Gift | −250,000 | — | — |
| Nov 12, 2025 | Chakma Justin Officer (Chief Business Officer) | Open-market sale | −30,000 | $8.91 | $267,300 |
| Nov 12, 2025 | Pratik Shah Director | Gift | −100,000 | — | — |
| Nov 12, 2025 | Chakma Justin Officer (Chief Business Officer) | Open-market sale | −136,380 | $8.86 | $1,208,327 |
| Aug 21, 2025 | Richard E. Lowenthal Director, Officer (PRESIDENT AND CEO), 10% owner | Open-market sale | −50,000 | $14.49 | $724,500 |
| Aug 21, 2025 | Kathleen D. Scott Officer (Chief Financial Officer) | Option exercise | +12,500 | $1.50 | $18,750 |
| Aug 21, 2025 | Kathleen D. Scott Officer (Chief Financial Officer) | Open-market sale | −12,500 | $15.00 | $187,500 |
| Aug 20, 2025 | Tanimoto Sarina Officer (CHIEF MEDICAL OFFICER), 10% owner | Open-market sale | −37,656 | $14.09 | $530,573 |
| Aug 19, 2025 | Tanimoto Sarina Officer (CHIEF MEDICAL OFFICER), 10% owner | Open-market sale | −12,344 | $14.03 | $173,186 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.